Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Medicenna Therapeutics Corp. successfully held its annual meeting, resulting in the re-election of all board nominees with high approval rates. Shareholders also approved the appointment of MNP LLP as the company’s auditor. This signifies continued investor confidence in Medicenna, a clinical-stage immunotherapy company developing innovative treatments for cancer and other diseases.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
